Axsome Therapeutics Stock Alpha and Beta Analysis
| AXSM Stock | USD 185.96 1.02 0.55% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Axsome Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Axsome Therapeutics over a specified time horizon. Remember, high Axsome Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Axsome Therapeutics' market risk premium analysis include:
Beta (0.30) | Alpha 0.59 | Risk 3.44 | Sharpe Ratio 0.17 | Expected Return 0.57 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Axsome Therapeutics Backtesting, Axsome Therapeutics Valuation, Axsome Therapeutics Correlation, Axsome Therapeutics Hype Analysis, Axsome Therapeutics Volatility, Axsome Therapeutics History and analyze Axsome Therapeutics Performance. Axsome Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Axsome Therapeutics market risk premium is the additional return an investor will receive from holding Axsome Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Axsome Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Axsome Therapeutics' performance over market.| α | 0.59 | β | -0.3 |
Axsome Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Axsome Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Axsome Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Axsome Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Axsome Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Axsome Therapeutics shares will generate the highest return on investment. By understating and applying Axsome Therapeutics stock market price indicators, traders can identify Axsome Therapeutics position entry and exit signals to maximize returns.
Axsome Therapeutics Return and Market Media
The median price of Axsome Therapeutics for the period between Mon, Oct 27, 2025 and Sun, Jan 25, 2026 is 148.17 with a coefficient of variation of 10.87. The daily time series for the period is distributed with a sample standard deviation of 16.48, arithmetic mean of 151.56, and mean deviation of 12.81. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | 11/14/2025 |
2 | Disposition of 10558 shares by Tabuteau Herriot of Axsome Therapeutics at 148.18 subject to Rule 16b-3 | 12/04/2025 |
3 | Axsome gets FDA review for Auvelity in Alzheimers agitation | 12/31/2025 |
4 | Disposition of 29450 shares by Tabuteau Herriot of Axsome Therapeutics at 172.33 subject to Rule 16b-3 | 01/06/2026 |
5 | Herriot Tabuteau Sells 78,703 Shares of Axsome Therapeutics Stock | 01/08/2026 |
6 | HALO or AXSM Which Is the Better Value Stock Right Now | 01/09/2026 |
7 | Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue | 01/12/2026 |
8 | Is Axsome Therapeutics Pricing Reflect Long Term Growth After Pipeline Milestones And 90 percent Rally | 01/13/2026 |
9 | Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia | 01/15/2026 |
10 | Disposition of 15000 shares by Mark Jacobson of Axsome Therapeutics at 4.85 subject to Rule 16b-3 | 01/16/2026 |
11 | Axsome Therapeutics Appears In Nasdaq Today CNS Discussions | 01/20/2026 |
12 | Axsome Therapeutics Valuation Check After Strong Recent Share Price Momentum | 01/21/2026 |
13 | Disposition of 12000 shares by Pizzie Nick of Axsome Therapeutics at 187.92 subject to Rule 16b-3 | 01/22/2026 |
14 | Piper Sandler Bullish on Axsome Therapeutics Ahead of Likely Auvelity Label Expansion by April 30 | 01/23/2026 |
About Axsome Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Axsome or other stocks. Alpha measures the amount that position in Axsome Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Payables Turnover | 0.64 | 0.46 | 0.42 | 0.44 | Days Of Inventory On Hand | 211.94 | 172.42 | 198.29 | 252.16 |
Axsome Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Axsome Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Axsome Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Axsome Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Axsome Therapeutics. Please utilize our Beneish M Score to check the likelihood of Axsome Therapeutics' management manipulating its earnings.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Axsome Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Axsome Therapeutics Backtesting, Axsome Therapeutics Valuation, Axsome Therapeutics Correlation, Axsome Therapeutics Hype Analysis, Axsome Therapeutics Volatility, Axsome Therapeutics History and analyze Axsome Therapeutics Performance. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Axsome Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.